Ophthalmological Therapeutics: Pipelines, Delivery Technologies, and Markets

By Hermann A.M. Mucke, PhD 

Tables

Table 3.1. Selected Artificial Tear Products Marketed in the United States and Europe

Table 3.2. Advanced Drug Candidates for Dry Eye Syndrome

Table 3.3. Antihistamines and Steroids for Topical Ocular Use in Allergic Conjunctivitis

Table 3.4. Newer Drugs for Intraocular Pressure Reduction Currently Used in the United States

Table 4.1. Sales and Revenue Figures for Visudyne and US Sales Share, 2000-2006

Table 4.2. Recent Patent Publications for Retinitis Pigmentosa

Table 5.1. Selected Alcon IP Documents Directed at Glaucoma and Published in 2006

Table 5.2. Allergan Net Sales for Selected Prescription OpHthalmology Drugs, 2002-2006

Table 5.3. Fovea Pharmaceuticals' Ophthalmological Drug Pipeline

Table 5.4. The Current US Prescription Ophthalmological Drug Market and its Projected Development Through 2015-2020

Figures

Figure 2.1. A Cross-Sectional Schematic of the Human Eye

Figure 3.1. Lens Transparency, Lens Aging, and Cataract Formation

Figure 3.2. Fluid Formation and Outflow Through the Trabecular Meshwork

Figure 4.1. Visual Acuity Changes in the US-European Phase III TAP Study Program for Visudyne